Endemicity is not a victory: the unmitigated downside risks of widespread SARS-CoV-2 transmission

Madison Stoddard, Alexander Novokhodko, Sharanya Sarkar, Debra Van Egeren, Laura F. White, Natasha S. Hochberg, Michael Rogers, Bruce Zetter, Diane Joseph-McCarthy, Arijit Chakravarty
doi: https://doi.org/10.1101/2022.03.29.22273146

Article Information

doi 
https://doi.org/10.1101/2022.03.29.22273146
History 
  • March 30, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Madison Stoddard1,
  2. Alexander Novokhodko2,
  3. Sharanya Sarkar3,
  4. Debra Van Egeren4,5,
  5. Laura F. White6,
  6. Natasha S. Hochberg6,7,
  7. Michael Rogers8,9,
  8. Bruce Zetter8,9,
  9. Diane Joseph-McCarthy6 and
  10. Arijit Chakravarty1,*
  1. 1Fractal Therapeutics, Cambridge, MA, USA
  2. 2University of Washington, Seattle, WA, USA
  3. 3Dartmouth College, Hanover, NH, USA
  4. 4Weill Cornell Medicine, New York, NY, USA
  5. 5New York Genome Center, New York, NY, USA
  6. 6Boston University, Boston, MA, USA
  7. 7Boston Medical Center, Boston, MA, USA
  8. 8Harvard Medical School, Boston, MA, USA
  9. 9Boston Children’s Hospital, Boston, MA, USA
  1. ↵*Corresponding author; email: arijit{at}fractaltx.com
Back to top
Posted March 30, 2022.
Download PDF
Data/Code
Email
Endemicity is not a victory: the unmitigated downside risks of widespread SARS-CoV-2 transmission
Madison Stoddard, Alexander Novokhodko, Sharanya Sarkar, Debra Van Egeren, Laura F. White, Natasha S. Hochberg, Michael Rogers, Bruce Zetter, Diane Joseph-McCarthy, Arijit Chakravarty
medRxiv 2022.03.29.22273146; doi: https://doi.org/10.1101/2022.03.29.22273146
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area